


peNirFP-N vector

The vector sequence has been compiled using the informa-tion from sequence databases, published literature, and other sources, together with partial sequences obtained by Evrogen. This vector has not been completely sequenced.



Product Cat.# Size peNirFP-N vector FP743 20 μ g mammalian expression vector Vector type NirFP Reporter Reporter codon usage mammalian Promoter for NirFP P_{CMV IE} Host cells mammalian Selection prokaryotic - kanamycin eukaryotic - neomycin (G418) Replication prokaryotic - pUC ori eukaryotic - SV40 ori Use NirFP expression in mammalian cells; generation of fusions to the NirFP N-terminus

Multiple cloning site (MCS)

Afe I	Xho I	Hind III	Pst I	Kpn I	Apa I BamH I*	Nco I*
Nhe I	Bgl II Sac I	E	EcoR I* Sal	Sac II	Sma I/Xma I Age I	NirFP
						≻
G.CTA.GCG.CTA.CCG.GAC	. TCA.GAT.CTC.GAG.CTC	. AAG. CTT. CGA.	ATT.CTG.CAG.TCG.	ACG.GTA.CCG.CGG	.GCC.CGG.GAT.CCA.CCG.G	TC.GCC.ACC.ATG.G
LALPD	S D L E L	KLR	ILQS	TVPR	ARDPP	V А Т М
* – not unique sites.						

Location of features

P_{CMV IE}: 1-589 Enhancer region: 59-465 TATA box: 554-560 Transcription start point: 583 MCS: 591-671 NirFF Kozak consensus translation initiation site: 672-682 Start codon (ATG): 679-681; Stop codon: 1381-1383 Fragment of human beta globin (HBB) gene: 1392-2510 Last 35 bp of HBB exon 2 : 1392-1426

HBB intron 2: 1427-2277

First 233 bp of HBB exon3: 2278-2510

SV40 early mRNA polyadenylation signal

Polyadenylation signals: 2652-2657 & 2681-2686 mRNA 3' ends: 2690 & 2702

f1 single-strand DNA origin: 2749-3204

Bacterial promoter for expression of Kan^r gene

-35 region: 3266-3271; -10 region: 3289-3294 Transcription start point: 3301

SV40 origin of replication: 3545-3680

SV40 early promoter

Enhancer (72-bp tandem repeats): 3378-3449 & 3450-3521

21-bp repeats: 3525-3545, 3546-3566 & 3568-3588 Early promoter element: 3601-3607

Major transcription start points: 3597, 3635, 3641 & 3646

Kanamycin/neomycin resistance gene Neomycin phosphotransferase coding sequences:

Start codon (ATG): 3729-3731; Stop codon: 4521-4523 G->A mutation to remove Pst I site: 3911

C->A (Arg to Ser) mutation to remove BssH II site: 4257 Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal

Polyadenylation signals: 4759-4764 & 4772-4777 pUC plasmid replication origin: 5108-5751

References

Gorman, C. (1985). "High efficiency gene transfer into mammalian cells." In: DNA cloning: A Practical Approach, Vol. II. Ed. by Glover. (IRL Press, Oxford, U.K.) Pp. 143-190

Haas, J. et al. (1996) "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." Curr Biol, 6 (3): 315-324 / pmid: 8805248

Kozak, M. (1987) "An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs." Nucleic Acids Res. 15 (20): 8125-8148 / pmid: 3313277

Vector description

peNirFP-N is a mammalian expression vector encoding near-infrared fluorescent protein NirFP. The vector allows generation of fusions to the NirFP N-terminus and expression of NirFP fusions or NirFP alone in eukaryotic (mammalian) cells.

NirFP codon usage is optimized for high expression in mammalian cells (humanized) [Haas et al. 1996]. To increase mRNA translation efficiency, Kozak consensus translation initiation site is generated upstream of the NirFP coding sequence [Kozak 1987]. Fragments of exons 2 and 3 and intron 2 of human beta globin gene are added in the 3' UTR of NirFP coding sequence in order to increase the protein expression level. Multiple cloning site (MCS) is located between $\mathsf{P}_{\mathsf{CMV}\,\mathsf{IE}}$ and NirFP coding sequence.

The vector backbone contains immediate early promoter of cytomegalovirus (P_{CMV IE}) for protein expression, SV40 origin for replication in mammalian cells expressing SV40 T-antigen, pUC origin of replication for propagation in E. coli, and f1 origin for single-stranded DNA production. SV40 polyadenylation signals (SV40 poly A) direct proper processing of the 3'-end of the reporter mRNA.

SV40 early promoter (P_{SV40}) provides neomycin resistance gene (Neo^r) expression to select stably transfected eukaryotic cells using G418. Bacterial promoter (P) provides kanamycin resistance gene expression (Kan^r) in E. coli. Kan^r/Neo^r gene is linked with herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signals.

Generation of NirFP fusion proteins

A localization signal or a gene of interest can be cloned into MCS of the vector. It will be expressed as a fusion to the NirFP N-terminus when inserted in the same reading frame as NirFP and no in-frame stop codons are present. The inserted sequence should contain an initiating ATG codon. NirFP-tagged fusions retain fluorescent properties of the native protein allowing fusion localization in vivo. Unmodified vector will express NirFP when transfected into eukaryotic (mammalian) cells.

Note: The plasmid DNA was isolated from dam⁺-methylated E.coli. Therefore some restriction sites are blocked by methylation. If you wish to digest the vector using such sites you will need to transform the vector into a dam host and make fresh DNA

Expression in mammalian cells

peNirFP-N vector can be transfected into mammalian cells by any known transfection method. CMV promoter provides strong, constitutive expression of NirFP or its fusions in eukaryotic cells. If required, stable transformants can be selected using G418 [Gorman 1985].

Propagation in E. coli

Suitable host strains for propagation in E. coli include DH5alpha, HB101, XL1-Blue, and other general purpose strains. Plasmid incompatibility group is pMB1/CoIE1. The vector confers resistance to kanamycin (30 µg/ml) to E. coli hosts. Copy number in E. coli is about 500.

Notice to Purchaser:

NirFP-related materials (also referred to as "Products") are intended for research use only

The Products are covered by U.S. Pat. 7,972,834; 8,138,320; European Pat. 1994149; and other Evrogen Patents and/or Patent applications pending. By use of these Products, you accept the terms and conditions of the applicable Limited Use Label License #001: http://www.evrogen.com/products/Evrogen-FP-license.shtml.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839, and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242